RA-ILD in the Spotlight at #ACR24 Over the past 5 years, there has been growing interest in RA-ILD due to its relative prevalence and severity. This seems to be one of the few RA outcomes not improving much, even with the advent of expanded treatment options.… https://t.co/MIPXW9EgVa https://t.co/kX0hDq8NTH